Molecular therapeutics: Methotrexate and its mechanism of action

Arthritis and Rheumatism

Volumn 39, Issue 12, 1996, Pages 1951-1960

  Cronstein, Bruce N ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; AMINOPHYLLINE; CYTOKINE; CYTOTOXIC AGENT; FOLIC ACID; FOLINIC ACID; LEUKOTRIENE; METHOTREXATE;

BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CYTOPENIA; DRUG MECHANISM; HUMAN; HUMORAL IMMUNITY; INFLAMMATION; NEUROTOXICITY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; STOMATITIS; SYNOVIUM;

ANTI-INFLAMMATORY AGENTS; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; METHOTREXATE;

EID: 0030462249     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.1780391203     Document Type: Review

References (109)

1. Gubner R, August S, Ginsberg V: Therapeutic suppression of tissue reactivity. II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Am J Med Sci 221:176-182, 1951
2. Weinblatt ME, Fraser P: Elevated mean corpuscular volume as a predictor of hematologic toxicity due to methotrexate therapy. Arthritis Rheum 32:1592-1596, 1989
3. Al-Awadhi A, Dale P, McKendry RJ: Pancytopenia associated with low dose methotrexate therapy: a regional survey. J Rheumatol 20:1121-1125, 1993
4. Morgan SL, Baggott JE, Vaughn WH, Young PK, Austin JV, Krumdieck CL, Alarcón GS: The effect of folic acid supplementation on the toxicity of low-dose methotrexate in patients with rheumatoid arthritis. Arthritis Rheum 33:9-18, 1990
5. Shiroky J, Neville C, Esdaile JM, Choquette D, Zummer M, Hazeltine M, Bykerk V, Kanji M, St-Pierre A, Robidoux L, Bourque L: Low-dose methotrexate with leucovorin (folinic acid) in the management of rheumatoid arthritis: results of a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 36:795-803, 1993
6. Morgan SL, Baggott JE, Vaughn WH, Austin JS, Veitch TA, Lee JY, Koopman WJ, Krumdieck CL, Alarcón GS: Supplementation with folic acid during methotrexate therapy for rheumatoid arthritis: a double-blind, placebo-controlled trial. Ann Intern Med 121:833-841, 1994
7. Baggott JE, Morgan SL, Ha T, Alarcón GS, Koopman WJ, Krumdieck CL: Antifolates in rheumatoid arthritis: a hypothetical mechanism of action. Clin Exp Rheumatol 11 (suppl 8):S101-S105, 1993
8. Weinblatt ME, Coblyn JS, Fox DA, Fraser PA, Holdsworth DE, Glass DN, Trentham DE: Efficacy of low-dose methotrexate in rheumatoid arthritis. N Engl J Med 312:818-822, 1985
9. Anderson PA, West SG, O'Dell JR, Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis: clinical and immunologic effects in a randomized double-blind study. Ann Intern Med 103:489-496, 1985
10. Kremer JM, Phelps CT: Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis: update after a mean of 90 months. Arthritis Rheum 35:138-145, 1992
11. Alarcón GS, Schrohenloher RE, Bartolucci AA, Ward JR, Williams HJ, Koopman WJ: Suppression of rheumatoid factor production by methotrexate in patients with rheumatoid arthritis: evidence for differential influences of therapy and clinical status on IgM and IgA rheumatoid factor expression. Arthritis Rheum 33:1156-1161, 1990
12. Moore S, Ruska K, Peters L, Olsen NJ: Associations of IgA and IgA-rheumatoid factor with disease features in patients with rheumatoid arthritis. Immunol Invest 23:355-365, 1994
13. Olsen NJ, Teal GP, Brooks RH: IgM-rheumatoid factor and responses to second-line drugs in rheumatoid arthritis. Agents Actions 34:169-171, 1991
14. Olsen NJ, Murray LM: Antiproliferative effects of methotrexate on peripheral blood mononuclear cells. Arthritis Rheum 32:378-385, 1989
15. Olsen NJ, Callahan LF, Pincus T: Immunologic studies of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 30:481-488, 1987
16. Feldmann M, Brennan FM, Maini RN: Rheumatoid arthritis. Cell 85:307-310, 1996
17. Moreland LW, Pratt PW, Mayes MD, Postlethwaite A, Weisman MH, Schnitzer T, Lightfoot R, Calabrese L, Zelinger DJ, Woody JN, Koopman WJ: Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 38:1581-1588, 1995
18. Van der Lubbe PA, Dijkmans BAC, Markusse HM, Nässander U, Breedveld FC: A randomized, double-blind, placebo-controlled study of CD4 monoclonal antibody therapy in early rheumatoid arthritis. Arthritis Rheum 38:1097-1106, 1995
19. Weinblatt ME, Trentham DE, Fraser PA, Holdsworth DE, Falchuk KR, Weissman BN, Coblyn JS: Long-term prospective trial of low-dose methotrexate in rheumatoid arthritis. Arthritis Rheum 31:167-175, 1988
20. Wascher TC, Hermann J, Brezinschek HP, Brezinschek R, Wilders-Truschnig M, Rainer F, Krejs GJ: Cell-type specific response of peripheral blood lymphocytes to methotrexate in the treatment of rheumatoid arthritis. Clin Invest 72:535-540, 1994
21. 4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. Arthritis Rheum 33:1149-1155, 1990
22. 4 synthesis ex vivo in neutrophils from patients with rheumatoid arthritis beginning treatment with methotrexate. Arthritis Rheum 35:376-384, 1992
23. Leroux JL, Damon M, Chavis C, Crastes de Paulet A, Blotman F: Effects of a single dose of methotrexate on 5- and 12-lipoxygenase products in patients with rheumatoid arthritis. J Rheumatol 19:863-866, 1992
24. Hawkes JS, Cleland LG, Proudman SM, James MJ: The effect of methotrexate on ex vivo lipoxygenase metabolism in neutrophils from patients with rheumatoid arthritis. J Rheumatol 21:55-58, 1994
25. Kremer JM, Lawrence DA, Jubiz W, DiGiacomo R, Rynes R, Bartholomew LE, Sherman M: Dietary fish oil and olive oil supplementation in patients with rheumatoid arthritis: clinical and immunologic effects. Arthritis Rheum 33:810-820, 1990
26. Kremer JM, Jubiz W, Michalek A, Rynes RI, Bartholomew LE, Bigaouette J, Timchalk M, Beeler D, Lininger L: Fish-oil fatty acid supplementation in active rheumatoid arthritis: a double-blinded, controlled, crossover study. Ann Intern Med 106:497-503, 1987
27. Kremer JM: The mechanism of action of methotrexate in rheumatoid arthritis: the search continues. J Rheumatol 21:1-5, 1994
28. Maini RN, Elliott MJ, Brennan FM, Williams RO, Chu CQ, Paleolog E, Charles PJ, Taylor PC, Feldmann M: Monoclonal anti-TNFα antibody as a probe of pathogenesis and therapy of rheumatoid disease. Immunol Rev 144:195-223, 1995
29. Hu SK, Mitcho YL, Oronsky AL, Kerwar SS: Studies on the effect of methotrexate on macrophage function. J Rheumatol 15:206-209, 1988
30. Connolly KM, Stecher VJ, Danis E, Pruden DJ, LaBrie T: Alteration of interleukin-1 production and the acute phase response following medication of adjuvant arthritic rats with cyclosporin-A or methotrexate. Int J Immunopharmacol 10:717-728, 1988
31. Chang DM, Baptiste P, Schur PH: The effect of antirheumatic drugs on interleukin 1 (IL-1) activity and IL-1 and IL-1 inhibitor production by human monocytes. J Rheumatol 17:1148-1157, 1990
32. Segal R, Mozes E, Yaron M, Tartakovsky B: The effects of methotrexate on the production and activity of interleukin-1. Arthritis Rheum 32:370-377, 1989
33. Meyer FA, Yaron I, Mashiah V, Yaron M: Methotrexate inhibits proliferation but not interleukin 1 stimulated secretory activities of cultured human synovial fibroblasts. J Rheumatol 20:238-242, 1993
34. Brody M, Bohm I, Bauer R: Mechanism of action of methotrexate: experimental evidence that methotrexate blocks the binding of interleukin 1β to the interleukin 1 receptor on target cells. Eur J Clin Chem Clin Biochem 31:667-674, 1993
35. Furst DE: Practical clinical pharmacology and drug interactions of low-dose methotrexate therapy in rheumatoid arthritis. Br J Rheumatol 34 (suppl 2):20-25, 1995
36. Chang DM, Weinblatt ME, Schur PH: The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. J Rheumatol 19:1678-1682, 1992
37. Thomas R, Carroll GJ: Reduction of leukocyte and interleukin-1β concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 36:1244-1252, 1993
38. Williams AS, Punn YL, Amos N, Cooper AM, Williams BD: The effect of liposomally conjugated methotrexate upon mediator release from human peripheral blood monocytes. Br J Rheumatol 34:241-245, 1995
39. Williams AS, Camilleri JP, Topley N, Williams BD: Prostaglandin and tumor necrosis factor secretion by peritoneal macrophages isolated from normal and arthritic rats treated with liposomal methotrexate. J Pharmacol Toxicol Methods 32:53-58, 1994
40. Williams AS, Topley N, Amos N, Williams BD: Effect of three lipophilic methotrexate derivatives upon mediator release by lipopolysaccharide-stimulated rat peritoneal macrophages. J Pharm Pharmacol 46:291-295, 1994
41. 2 release by lipopolysaccharide stimulated rat peritoneal macrophages. Biochim Biophys Acta 1225:217-222, 1994
42. Smith-Oliver T, Noel LS, Stimpson SS, Yarnall DP, Connolly KM: Elevated levels of TNF in the joints of adjuvant arthritic rats. Cytokine 5:298-304, 1993
43. Seitz M, Loetscher P, Dewald B, Towbin H, Rordorf C, Gallati H, Baggiolini M, Gerber NJ: Methotrexate action in rheumatoid arthritis: stimulation of cytokine inhibitor and inhibition of chemokine production by peripheral blood mononuclear cells. Br J Rheumatol 34:602-609, 1995
44. Barrera P, Haagsma CJ, Boerbooms AMT, van Riel PLC, Borm GF, van de Putte LBA, van der Meer JWM: Effect of methotrexate alone or in combination with sulphasalazine on the production and circulating concentrations of cytokines and their antagonists: longitudinal evaluation in patients with rheumatoid arthritis. Br J Rheumatol 34:747-755, 1995
45. Barrera P, Boerbooms AMT, Janssen EM, Sauerwein RW, Gallati H, Mulder J, de Boo T, Demacker PNM, van de Putte LBA, van der Meer JWM: Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum 36:1070-1079, 1993
46. Crilly A, McInness IB, McDonald AG, Watson J, Capell HA, Madhok R: Interleukin 6 (IL-6) and soluble IL-2 receptor levels in patients with rheumatoid arthritis treated with low dose oral methotrexate. J Rheumatol 22:224-226, 1995
47. Lacki JK, Klama K, Mackiewicz SH, Mackiewicz U, Muller W: Circulating interleukin-10 and interleukin-6 serum levels in rheumatoid arthritis patients treated with methotrexate or gold salts: preliminary report. Inflamm Res 44:24-26, 1995
48. Wascher TC, Hermann J, Brezinschek R, Brezinschek HP, Wilders-Truschnig M, Rainer F, Krejs GJ: Serum levels of interleukin-6 and tumour-necrosis-factor-alpha are not correlated to disease activity in patients with rheumatoid arthritis after treatment with low-dose methotrexate. Eur J Clin Invest 24:73-75, 1994
49. Seitz M, Dewald B, Ceska M, Gerber N, Baggiolini M: Interleukin-8 in inflammatory rheumatic diseases: synovial fluid levels, relation to rheumatoid factors, production by mononuclear cells, and effects of gold sodium thiomalate and methotrexate. Rheumatol Int 12:159-164, 1992
50. Loetscher P, Dewald B, Baggiolini M, Seitz M: Monocyte chemoattractant protein 1 and interleukin 8 production by rheumatoid synoviocytes: effects of anti-rheumatic drugs. Cytokine 6:162-170, 1994
51. Hershfield MS, Krodich NM: S-adenosylhomocysteine hydrolase is an adenosine-binding protein: a target for adenosine toxicity. Science 202:757-760, 1978
52. Kredich NM, Martin DV Jr: Role of S-adenosylhomocysteine in adenosine mediated toxicity in cultured mouse T lymphoma cells. Cell 12:931-938, 1977
53. Hershfield MS, Kurtzberg J, Aiyar VN, Suh EJ, Schiff R: Abnormalities in S-adenosylhomocysteine hydrolysis, ATP catabolism, and lymphoid differentiation in adenosine deaminase deficiency. Ann N Y Acad Sci 451:78-86, 1985
54. Palella TD, Schatz RA, Wilens TE, Fox IH: S-Adenosylhomocysteine accumulation and selective cytotoxicity in cultured T- and B-lymphocytes. J Lab Clin Med 100:269-278, 1982
55. Pike MC, Snyderman R: Transmethylation reactions regulate affinity and functional activity of chemotactic factor receptors on macrophages. Cell 28:107-114, 1982
56. Pike MC, Kredich NM, Snyderman R: Requirement of S-adenosyl-L-methionine-mediated methylation for human monocyte chemotaxis. Proc Natl Acad Sci U S A 75:3928-3932, 1978
57. Johnston JM, Kredich NM: Inhibition of methylation by adenosine in adenosine deaminase-inhibited, phytohemagglutinin-stimulated human lymphocytes. J Immunol 123:97-103, 1979
58. Furumitsu Y, Yukioka K, Kojima A, Yukioka M, Shichikawa K, Ochi T, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H: Levels of urinary polyamines in patients with rheumatoid arthritis. J Rheumatol 20:1661-1665, 1993
59. Yukioka K, Wakitani S, Yukioka M, Furumitsu Y, Shichikawa K, Ochi T, Goto H, Matsui-Yuasa I, Otani S, Nishizawa Y, Morii H: Polyamine levels in synovial tissues and synovial fluids of patients with rheumatoid arthritis. J Rheumatol 19:689-692, 1992
60. Flescher E, Bowlin TL, Talal N: Regulation of IL-2 production by mononuclear cells from rheumatoid arthritis synovial fluids. Clin Exp Immunol 87:435-437, 1992
61. Flescher E, Bowlin TL, Ballester A, Houk R, Talal N: Increased polyamines may downregulate interleukin 2 production in rheumatoid arthritis. J Clin Invest 83:1356-1362, 1989
62. Miyasaka N, Nakamura T, Russell IJ, Talal N: Interleukin 2 deficiencies in rheumatoid arthritis and systemic lupus erythematosus. Clin Immunol Immunopathol 31:109-117, 1984
63. Miyasaka N, Murota N, Yamaoka K, Sato K, Yamada T, Nishido T, Okumura K: Interleukin 2 defect in the peripheral blood and the lung in patients with Sjögren's syndrome. Clin Exp Immunol 65:497-505, 1986
64. Nesher G, Moore TL: The in vitro effects of methotrexate on peripheral blood mononuclear cells: modulation by methyl donors and spermidine. Arthritis Rheum 33:954-959, 1990
65. Nesher G, Moore TL, Dorner RW: In vitro effects of methotrexate on peripheral blood monocytes: modulation by folinic acid and S-adenosylmethionine. Ann Rheum Dis 50:637-641, 1991
66. Krenitsky TA, Rideout JL, Chao EY, Koszalka GW, Gurney F, Crouch RC, Cohn NK, Wolberg G, Vinegar R: Imidazo[4,5-c]-pyridines (3-deazapurines) and their nucleosides as immunosuppressive and antiinflammatory agents. J Med Chem 29:138-143, 1986
67. Jurgensen CH, Huber BE, Zimmerman TP, Wolberg G: 3-deazaadenosine inhibits leukocyte adhesion and ICAM-1 biosynthesis in tumor necrosis factor-stimulated human endothelial cells. J Immunol 144:653-661, 1990
68. Jurgensen CH, Wolberg G, Zimmerman TP: Inhibition of neutrophil adherence to endothelial cells by 3-deazaadenosine. Agents Actions 27:398-400, 1989
69. Fantone JC, Duque RE, Davis BH, Phan SH: 3-deazaadenosine inhibition of stimulus-response coupling in human polymorphonuclear leukocytes. J Leukoc Biol 45:121-128, 1989
70. Leonard EJ, Skeel A, Chiang PK, Cantoni GL: The action of the adenosylhomocysteine hydrolase inhibitor, 3-deazaadenosine, on phagocytic function of mouse macrophages and human monocytes. Biochem Biophys Res Commun 84:102-109, 1978
71. Zimmerman TP, Wolberg G, Duncan GS: Inhibition of lymphocyte-mediated cytolysis by 3-deazaadenosine: evidence for a methylation reaction essential for cytolysis. Proc Natl Acad Sci USA 75:6220-6224, 1978
72. Smith DM, Johnson JA, Turner RA: Biochemical perturbations of BW 91Y (3-deazaadenosine) on human neutrophil chemotactic potential and lipid metabolism. Int J Tissue React 13:1-18, 1991
73. Sung SSJ, Silverstein SC: Inhibition of macrophage phagocytosis by methylation inhibitors: lack of correlation of protein carboxymethylation and phospholipid methylation with phagocytosis. J Biol Chem 260:546-554, 1985
74. Stopford CR, Wolberg G, Prus KL, Reynolds-Vaughn R, Zimmerman TP: 3-Deazaadenosine-induced disorganization of macrophage microfilaments. Proc Natl Acad Sci U S A 82:4060-4064, 1985
75. Zimmerman TP, Iannone M, Wolberg G: 3-Deazaadenosine: S-adenosylhomocysteine hydrolase-independent mechanism of action in mouse lymphocytes. J Biol Chem 259:1122-1126, 1984
76. Chabner BA, Allegra CJ, Curt GA, Clendeninn NJ, Baram J, Koizumi S, Drake JC, Jolivet J: Polyglutamation of methotrexate: is methotrexate a prodrug? J Clin Invest 76:907-912, 1985
77. Allegra CJ, Drake JC, Jolivet J, Chabner BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci U S A 82:4881-4885, 1985
78. Baggott JE, Vaughn WH, Hudson BB: Inhibition of 5-aminoimidazole-4-carboxamide ribotide transformylase, adenosine deaminase and 5′-adenylate deaminase by polyglutamates of methotrexate and oxidized folates and by 5-aminoimidazole-4-carboxamide riboside and ribotide. Biochem J 236:193-200, 1986
79. Ha T, Morgan SL, Vaughan WH, Baggott JE: Inhibition of adenosine deaminase and S-adenosyl homocysteine hydrolase by 5-aminoimidazole-4-carboxamide riboside. FASEB J 6:1210-1215, 1992
80. Luhby AL, Cooperman JH: Aminoimidazole carboxamide excretion in vitamin B12 and folic acid deficiencies. Lancet 2:1381-1382, 1962
81. Cronstein BN, Eberle MA, Gruber HE, Levin RI: Methotrexate inhibits neutrophil function by stimulating adenosine release from connective tissue cells. Proc Natl Acad Sci U S A 88:2441-2445, 1991
82. Cronstein BN, Naime D, Ostad E: The antiinflammatory mechanism of methotrexate: increased adenosine release at inflamed sites diminishes leukocyte accumulation in an in vivo model of inflammation. J Clin Invest 92:2675-2682, 1993
83. Asako H, Kubes P, Baethge B, Wolf R, Granger DN: Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 16:45-56, 1992
84. Asako H, Wolf RE, Granger DN: Leukocyte adherence in rat mesenteric venules: effects of adenosine and methotrexate. Gastroenterology 104:31-37, 1993
85. Firestein GS, Boyle D, Bullough DA, Gruber HE, Sajjadi FG, Montag A, Sambol B, Mullane K: Protective effect of an adenosine kinase inhibitor in septic shock. J Immunol 152:5853-5859, 1994
86. Firestein GS, Bullough DA, Erion MD, Jimenez R, Ramirez-Weinhouse M, Barankiewicz J, Smith CW, Gruber HE, Mullane KM: Inhibition of neutrophil adhesion by adenosine and an adenosine kinase inhibitor: the role of selectins. J Immunol 154:326-334, 1995
87. Rosengren S, Bong GW, Firestein GS: Anti-inflammatory effects of an adenosine kinase inhibitor: decreased neutrophil accumulation and vascular leakage. J Immunol 154:5444-5451, 1995
88. Cronstein BN, Naime D, Firestein GS: The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 38:1040-1045, 1995
89. Gadangi P, Longaker M, Naime D, Levin RI, Recht PA, Montesinos MC, Buckley MT, Carlin G, Cronstein BN: The antiinflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 156:1937-1941, 1996
90. Baggott JE, Morgan SL, Ha T, Vaughn WH, Hine RJ: Inhibition of folate-dependent enzymes by non-steroidal anti-inflammatory drugs. Biochem J 282:197-202, 1992
91. Bernini JC, Fort DW, Griener JC, Kane BJ, Chappell WB, Kamen BA: Aminophylline for methotrexate-induced neurotoxicity. Lancet 345:544-547, 1995
92. Cronstein BN, Levin RI, Belanoff J, Weissmann G, Hirschhorn R: Adenosine: an endogenous inhibitor of neutrophil-mediated injury to endothelial cells. J Clin Invest 78:760-770, 1986
93. Cronstein BN, Kramer SB, Weissmann G, Hirschhorn R: Adenosine: a physiological modulator of superoxide anion generation by human neutrophils. J Exp Med 158:1160-1177, 1983
94. - generation, respectively. J Clin Invest 85:1150-1157, 1990
95. Salmon JE, Cronstein BN: Fcγ receptor-mediated functions in neutrophils are modulated by adenosine receptor occupancy: A1 receptors are stimulatory and A2 receptors are inhibitory. J Immunol 145:2235-2240, 1990
96. Cronstein BN, Levin RI, Philips MR, Hirschhorn R, Abramson SB, Weissmann G: Neutrophil adherence to endothelium is enhanced via adenosine A1 receptors and inhibited via adenosine A2 receptors. J Immunol 148:2201-2206, 1992
97. Kammer GM, Birch RE, Polmar SH: Impaired immunoregulation in systemic lupus erythematosus: defective adenosine-induced suppressor T lymphocyte generation. J Immunol 130: 1706-1712, 1983
98. Schultz LA, Kammer GM, Rudolph SA: Characterization of the human T lymphocyte adenosine receptor: comparison of normal and systemic lupus erythematosus cells. FASEB J 2:244-250, 1988
99. Mandler R, Birch RE, Polmar SH, Kammer GM, Rudolph SA: Abnormal adenosine-induced immunosuppression and cAMP metabolism in T lymphocytes of patients with systemic lupus erythematosus. Proc Natl Acad Sci U S A 79:7542-7546, 1982
100. Kammer GM, Rudolph SA: Regulation of human T lymphocyte surface antigen mobility by purinergic receptors. J Immunol 133:3298-3302, 1984
101. Kammer GM, Smith JA, Mitchell R: Capping of human T-cell specific determinants: kinetics of capping and receptor reexpression and regulation by the cytoskeleton. J Immunol 130: 38-44, 1983
102. Dong RP, Kameoka J, Hegen M, Tanaka T, Xu Y, Schlossman SF, Morimoto C: Characterization of adenosine deaminase binding to human CD26 on T cells and its biologic role in immune response. J Immunol 156:1349-1355, 1996
103. Parmely MJ, Zhou W-W, Edwards CK III, Borcherding DR, Silverstein R, Morrison DC: Adenosine and a related carbocyclic nucleoside analogue selectively inhibit tumor necrosis factor-alpha production and protect mice against endotoxin challenge. J Immunol 151:389-396, 1993
104. Bouma MG, Stad RK, van den Wildenberg FAJM, Buurman WA: Differential regulatory effects of adenosine on cytokine release by activated human monocytes. J Immunol 153:4159-4168, 1994
105. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, Firestein GS: Inhibition of TNFα expression by adenosine: role of A3 adenosine receptors. J Immunol 156:3435-3442, 1996
106. Le Moine O, Stordeur P, Schandené L, Marchant A, de Groote D, Goldman M, Devière J: Adenosine enhances IL-10 secretion by human monocytes. J Immunol 156:4408-4414, 1996
107. Firestein GS, Paine MM, Boyle DL: Mechanisms of methotrexate action in rheumatoid arthritis: selective decrease in synovial collagenase gene expression. Arthritis Rheum 37:193-200, 1994
108. Boyle DL, Sajjadi FG, Firestein GS: Inhibition of synoviocyte collagenase gene expression by adenosine receptor stimulation. Arthritis Rheum 39:923-930, 1996
109. Merrill JT, Coffey D, Shen C, Zakharenko O, Zhang HW, Lahita RG, Cronstein BN: Mechanisms of rheumatoid nodulosis: methotrexate-enhanced monocyte fusion requires protein synthesis and intact microtubules (abstract). Arthritis Rheum 38 (suppl 9):S157, 1995